3.7100
0.0000
(0.00%)
As of April 3 at 4:00:00 PM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
89,539
89,539
139,989
142,797
87,728
Cost of Revenue
49,812
49,812
70,808
60,157
41,655
Gross Profit
39,727
39,727
69,181
82,640
46,073
Operating Expense
124,691
124,691
99,350
61,707
50,936
Operating Income
-84,964
-84,964
-30,169
20,933
-4,863
Net Non Operating Interest Income Expense
-6,289
-6,289
-7,781
-888
-878
Pretax Income
-188,527
-188,527
-45,976
19,880
-6,572
Tax Provision
-4,365
-4,365
-817
869
-327
Net Income Common Stockholders
-157,490
-157,490
-39,157
19,011
-6,245
Diluted NI Available to Com Stockholders
-157,490
-157,490
-39,157
19,011
-6,245
Basic EPS
-1.63
-1.63
-0.41
0.23
-0.08
Diluted EPS
-1.63
-1.63
-0.41
0.22
-0.08
Basic Average Shares
96,555.3470
96,555.3470
94,829.8920
83,484.1730
79,944.9110
Diluted Average Shares
96,555.3470
96,555.3470
94,829.8920
85,618.6670
79,944.9110
Total Operating Income as Reported
-184,174
-184,174
-30,220
20,768
-5,694
Rent Expense Supplemental
249
249
231
236
173
Total Expenses
174,503
174,503
170,158
121,864
92,591
Net Income from Continuing & Discontinued Operation
-157,490
-157,490
-39,157
19,011
-6,245
Normalized Income
-60,577.0272
-60,577.0272
-39,106.9063
19,168.7875
-5,455.3477
Interest Income
4,910
4,910
973
--
34
Interest Expense
11,199
11,199
8,754
888
912
Net Interest Income
-6,289
-6,289
-7,781
-888
-878
EBIT
-177,328
-177,328
-37,222
20,768
-5,660
EBITDA
-148,618
-148,618
-10,863
33,224
4,179
Reconciled Cost of Revenue
49,812
49,812
70,808
60,157
41,655
Reconciled Depreciation
28,710
28,710
26,359
12,456
9,839
Net Income from Continuing Operation Net Minority Interest
-157,490
-157,490
-39,157
19,011
-6,245
Total Unusual Items Excluding Goodwill
-99,210
-99,210
-51
-165
-831
Total Unusual Items
-99,210
-99,210
-51
-165
-831
Normalized EBITDA
-49,408
-49,408
-10,812
33,389
5,010
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-2,297.0272
-2,297.0272
-0.9063
-7.2125
-41.3477
12/31/2020 - 1/11/2002
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
KAN.ST Kancera AB (publ)
1.1020
-1.61%
SCLP.L Scancell Holdings plc
8.15
0.00%
SNG.L Synairgen plc
0.9500
-9.52%
RNAC Cartesian Therapeutics, Inc.
10.41
-15.64%
RZLT Rezolute, Inc.
2.5650
-6.35%
INZY Inozyme Pharma, Inc.
0.8102
-7.46%
LXEO Lexeo Therapeutics, Inc.
2.3600
-10.61%
BCYC Bicycle Therapeutics plc
7.03
-5.39%
LRMR Larimar Therapeutics, Inc.
1.9200
-3.03%
MRVI Maravai LifeSciences Holdings, Inc.
1.9700
-6.19%